LIFESTYLE - Here's why you must have sex everyday - INDIA

Have you ever heard that song called Sexual Healing? It's not just a metaphor. Sex can actually heal. It can heal your body and mind and prevent lots of diseases.

Some say it's the first medicine ever known to man and it should be administered daily. Sounds too good to be true? Let's discover the four reasons for which a man should have sex each day.

Great form of exercise
Making love is a form of physical activity. During intercourse, the physiological changes in your body are consistent with a workout. You must have noticed that the respiratory rate rises, which means you get tired. Hence, you burn calories. If you have sex three times a week for 15 minutes (but we know you can do better than that) you'll burn about 7.500 calories in a year. That's the equivalent of jogging 75 miles! Heavy breathing raises the amount of oxygen in your cells, and the testosterone produced during sex keeps your bones and muscles strong.

Pain relief
The "Honey, not today, I have a headache" cannot be an excuse any more. During sex, both male and female bodies produce endorphins, hormones that act as weak painkillers. A study conducted by Gina Ogden showed that during sexual stimulation and especially during orgasm, we don't feel pain. If she finds another excuse, remind her that sex is good for her entire reproductive system, because it trains the PC muscle, which keeps the reproductive organs in shape. In women, sex can also increase fertility, postpone the menopause and relieve PMS symptoms.

Prostate protection
Most of the fluid you ejaculate is secreted by the prostate gland. If you stop ejaculating, the fluid stays in the gland, which tends to swell, causing lots of problems. Regular ejaculation will wash those fluids out and ensure the well being of your prostate until old age. Problems may also occur when you suddenly change the frequency of ejaculations.

Prevents erectile dysfunctions
Fifty per cent of men older than 40 suffer from erectile dysfunctions and all young men fear the moment when they won't be able to get it up any more. The best medicine against impotence is...sex. An erection keeps the blood flowing through your penile arteries, so the tissue stays healthy. Plus, doctors compare an erection to an athletic reflex: the more you train the more capable you are to perform.

Stress relief
It's a scientific fact: sex can be a very effective way of reducing stress levels. During sex your body produces dopamine, a substance that fights stress hormones, endorphins, aka "happiness hormones" and oxytocin, a desire-enhancing hormone secreted by the pituitary gland.

HEALTH - FRANCE

Two new promising treatments against aggressive skin cancer

The Monde.fr with AFP . 04.06.2012 at 10: 54 • updated 04.06.2012 at 10: 54

The strong growth of the France skin cancers is explained by the evolution of the exposure to sunlight and artificial UV patterns. | AFP/ALAIN JOCARD

After more than three decades without new treatment for advanced melanoma, laboratories are developing these last years of the effective weapons against the aggressive cancer of the skin, which the last two were unveiled Monday 4 June in the United States. These two new officers, the Dabrafenib and the Trametinib, both produced by the British pharmaceutical firm GlaxoSmithKline, are anti-cancer precision targeting of tumor specific mechanisms.
DECREASE IN THE RISK OF PROGRESSION OF TUMOR
The Trametinib neutralizes a protein called MEK, which contributes to the growth of cancer. The Dabrafenib prevents it gene mutant BRAF to produce a protein that boosts the progression of melanoma, cancer has the highest in the world. Patients in the study with the Trametinib experienced a median time of 4.8 months during which their cancer has not progressed compared to a month and a half in the group subject to standard chemotherapy, is a reduction of 55% of the risk of spread of the tumor.
These patients also saw their risk of dying decreased by 46% compared to those treated with chemotherapy, said Dr. Caroline Robert, head of the Department of Dermatology at the Institute Gustave-Roussy in Villejuif, who led this clinical trial of phase 3 in which 322 patients participated. "The Trametinib will probably become another treatment of first line for treating advanced melanoma", predicted, confident.
The second clinical trial with the Dabrafenib showed a decline of 70% of the risk of progression of melanoma in participants compared to those treated with standard chemotherapy (5.1 months compared with 2.7 months). 250 Participants in this study of phase 3, of which 187 have been treated with the Dabrafenib, had not been previously treated and suffered from an inoperable melanoma, said Dr. Axel Hauschild, Professor of Dermatology at the University Hospital of Keil in Germany, the principal investigator. Overall survival data are not yet sufficiently complete, he added. In addition, Dr. Hauschild said that patients in the Dabrafenib Group had serious side effects of the skin.

80% OF SKIN CANCER ARE MELANOMA
These clinical studies were presented to the 48^e Annual Conference of theAmerican Society of Clinical Oncology meeting this weekend in Chicago, where several other significant advances were announced, including against advanced breast and prostate cancer. So far the Zelboraf (Vemurafenib) of the Swiss laboratory Roche is only targeted therapy that has been authorized, in 2011, by the authorities of the drugs in the United States (FDA) and Europe to treat advanced melanoma. This treatment targets the gene mutant BRAF, present in half of metastasized melanoma.
"For three decades we have no new treatment for metastatic melanoma but now we are quickly catching up with us", said to the press Dr. Hauschild. In 2011, the FDA approved time two treatments for melanoma, Zelboraf of rock and Yervoy (Ipilimumab) of the U.S. laboratory Bristol-Myers Squibb, an antibody that stimulates the immune system; the next would be Dabrafenib. "The results of the clinical trial with the Dabrafenib represent a new advance against melanoma and establish one basis for other clinical studies to evaluate the role of the Dabrafenib in combination with other anticancer", found this doctor.
GlaxoSmithKline announced May 29 the start of a clinical trial of phase 3 combining the Dabrafenib and the Trametinib. For analysts from Citigroup, the success of the Dabrafenib and the Trametinib could steal the spotlight at the rock Zelboraf, which paved the way for these new anticancer. According to the World Health Organization, the skin cancer is 66 000 deaths per year in the world, of which about 80% are melanoma. M